Agilent Technologies Acquires ACEA Biosciences to Strengthen Platform and Capabilities in Cell Analysis

 Agilent Technologies Acquires ACEA Biosciences to Strengthen Platform and Capabilities in Cell Analysis

Agilent Technologies Acquires ACEA Biosciences to Strengthen Platform and Capabilities in Cell Analysis

Shots:

  • ACEA to receive $250M in upfront cash as a total deal value, adding a differentiated portfolio and organizational capabilities in cell analysis
  • Agilent will get hold of ACEA’s CFDA and CE-IVD labelled cytometer configuration, i.e. NovoCyte flow cytometer and xCELLigence Real-Time Cell analyzer used for monitoring growth, function, and cellular responses of cells
  • The acquisition will expand Agilent’s R&D, manufacturing & operations, and commercial capabilities and coverage in China

Click here to read full press release/ article | Ref: Agilent Technologies | Image: Pr web

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post